Compare FBRX & BCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBRX | BCAR |
|---|---|---|
| Founded | N/A | 2025 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 417.6M |
| IPO Year | 2017 | N/A |
| Metric | FBRX | BCAR |
|---|---|---|
| Price | $19.12 | $10.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | 178.8K | ★ 720.0K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.78 | $9.89 |
| 52 Week High | $35.80 | $10.89 |
| Indicator | FBRX | BCAR |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 71.13 |
| Support Level | $18.18 | $10.04 |
| Resistance Level | $34.44 | N/A |
| Average True Range (ATR) | 2.09 | 0.21 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 5.88 | 84.25 |
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
D Boral ARC Acquisition I Corp is a blank check company.